News
-
-
-
COMMUNIQUÉ DE PRESSE
Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG
Xlife Sciences AG provides updates on ongoing transactions with Grupo Landsteiner and the NASDAQ listing of VERAXA Biotech AG, aiming to accelerate project development and corporate growth -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence
Xlife Sciences AG announces transition to the main segment of SIX Swiss Exchange to strengthen market presence, with advantages like increased visibility, improved liquidity, and stronger recognition in capital markets -
-
-
COMMUNIQUÉ DE PRESSE
Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio
Xlife Sciences AG announces the award-winning world's first liver-specific PET tracer, DAZAmed, highlighting scientific and commercial potential. A breakthrough in nuclear medicine for liver disease imaging -